Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue

Prostate

Volumn 63, Issue 1, 2005, Pages 13-18

  Steuber, Thomas ^a,e   Niemela, Pauliina ^b   Haese, Alexander ^a   Pettersson, Kim ^b   Erbersdobler, Andreas ^a   Chun, K H Felix ^a   Graefen, Markus ^a   Kattan, Michael W ^c   Huland, Hartwig ^a   Lilja, Hans ^c,d  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF TURKU   (Finland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Benign prostate hyperplasia; Free prostate specific antigen; Free prostate specific antigen subforms; Human kallikrein 2; Prostate cancer

Indexed keywords

FREE PROSTATE SPECIFIC ANTIGEN; HUMAN KALLIKREIN 2; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REGRESSION ANALYSIS; SERUM; STATISTICAL ANALYSIS;

AGED; BIOLOGICAL MARKERS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TISSUE KALLIKREINS;

EID: 20144362578     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20156     Document Type: Article

References (25)

1. Oesterling I, Jacobsen SJ, Chute C. Serum prostate-specific-antigen in a community based population of healthy men. JAMA 1993;270:860-864.
2. Bonilla J, Roehrborn CG, McConnel JD. Patterns of prostate growth observed in placebo treated patients in the PLESS trial over four years (abstract). J Urol 1995;159(Suppl 5):301 A.
3. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53(3):581-589.
4. Morote J, Encabo G, Lopez M, de Torres IM. Prediction of prostate volume based on total and free serum prostate-specific antigen: Is it reliable? Eur Urol 2000;38(1):91-95.
5. Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H. Discrimination of prostate cancer from, benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal, cleavage site at Lys145-Lys146. Clin Chem 2001;47:1415-1423.
6. Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P, Huland H, Lilja H. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002;168(5): 1917-1922
7. (Erratum in: J Urol 2003;169(1):295).
8. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000;60(3):756-759.
9. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, Evans CL, Gasior CL, Linton HJ, Carpenter P, Rittenhouse HG. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61(18):6958-6963.
10. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CC, Linton HJ, Harringer W, Klocker H, Mikolajczyk SD. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003;170:2181.
11. Haese A, Graefen M, Steuber T, Huland H, Lilja H. Total and Gleason grade 4/5 cancer volumes, are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by, benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 2003;170:2269.
12. Mitrunen K, Pettersson K, Piironen T, BjorkT, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-1120.
13. Nurmikko P, Vaisanen V, Piironen T, Lindgren S, Lilja H, Pettersson K. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000;46:1610-1618.
14. Mc Neal JE, Redwine EA, Freiha FS, Stamey TS. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897.
15. Sobin LH, Fleming ID. TNM Classification of malignant tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80: 1803.
16. Schmid HP, Mc Neal JE. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J Surg Pathol 1992;16:184.
17. Henke RP, Krüger E, Ayhan N, Hübner D, Hammerer P, Huland H. Immunhistochemical detection of p53 protein in human prostatic cancer. J Urol 1994;152:1297-1301.
18. Haese A, Khan MA, Sokoll LJ. Total, free, and complexed PSA and hK2 for early detection of prostate cancer. MLO Med Lab Obs 2003;35:14.
19. Haese A, Graefen M, Becker C, Huland H, Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003;54:181.
20. Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997;158:1606-1609.
21. Naya Y, Pritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Urology 2004;63:492.
22. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, Marks LS, Song W, Wheeler TM, Slawin KM. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55(1):41-45.
23. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003; 49(2):253-259.
24. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004;63:905-910.
25. Piironen T, Petterson K, Suonpaa M, Stenman UH, Oesterling JE, Lilja H. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996;48(Suppl 6A):81.